Antiphospholipid antibodies in pregnancy: prevalence and clinical associations.
OBJECTIVE
To determine prevalence, clinical association and predictive power of antiphospholipid antibodies in pregnancy.


METHODS
To test for the presence of anticardiolipin antibodies and lupus anticoagulant in order to confirm prevalence data which imply that each antibody has the same clinical significance. A detailed obstetric history and the outcome measures were obtained from each patient in the study.


METHODS
National Women's Hospital, Auckland, New Zealand.


METHODS
Nine hundred and thirty-three consecutively booked pregnant women.


METHODS
Prevalence of auto-antibodies; perinatal morbidity and mortality; incidence of pre-eclampsia, growth retardation and fetal distress.


RESULTS
Nine women (1.0%) had anticardiolipin antibodies, 11 (1.2%) had lupus anticoagulant and two had both antibodies. The fetal mortality rate for women with antibodies was 167/1000. Pre-eclampsia occurred significantly more often in women with auto-antibodies.


CONCLUSIONS
The presence of antiphospholipid antibodies is frequently associated with adverse pregnancy outcome (9/18 pregnancies). High titre anticardiolipin antibodies carry a poor prognosis.
Pattison
N S
NS
Department of Obstetrics & Gynaecology, University of Auckland, National Women's Hospital, New Zealand.
Chamley
L W
LW
McKay
E J
EJ
Liggins
G C
GC
Butler
W S
WS
D000293:Adolescent; D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000032:analysis*; D001323:Autoantibodies / Q000032:analysis; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000276:immunology; D011247:Pregnancy / Q000276:immunology*; D011256:Pregnancy Outcome; D012680:Sensitivity and Specificity
D017153:Antibodies, Anticardiolipin; D001323:Autoantibodies; D016682:Lupus Coagulation Inhibitor